February 07, 2019
1 min watch

VIDEO: Eyenovia’s MicroStat shows positive phase 3 data

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

SAN FRANCISCO — Michael Rowe, vice president of marketing for Eyenovia, discusses results of the MIST-1 trial of MicroStat, a fixed combination of phenylephrine 2.5% and tropicamide 1%, and demonstrates how Eyenovia’s OpteJet technology works at the Glaucoma 360: New Horizons Forum.